Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial
Preprint
- 1 January 2020
- preprint
- Published by Elsevier in SSRN Electronic Journal
Abstract
The combination of PD-L1-inhibitor durvalumab and PARP-inhibitor olaparib (DOP) in addition to standard neoadjuvant chemotherapy was investigated in the phase II I-SPY2 platform trial of stage II/III HER2-negative breast cancer. Seventy-three HER2-negative participants were randomized to DOP and 299 to standard of care control. DOP graduated in all subtypes, increasing pCR rates in all HER2-negative (22 to 37%), HR-positive/HER2-negative (14% to 28%), TNBC (27% to 47%). In HR-positive/HER2-negative cancers, pCR rate in MammaPrint ultra high (MP2) cases was considerably higher than MP1, 64% vs 22%. Overall,12.3% of patients in the experimental arm experienced immune-related grade 3 adverse events vs. 1.3% in control. Gene expression signatures associated with immune response were positively associated with pCR in both arms, while a mast cell signature was associated with non-pCR. DOP has potential benefits over standard neoadjuvant therapy in HER2-negative early breast cancer, particularly in a highly sensitive subset of high-risk HR-positive/HER2-negative patients.Keywords
This publication has 20 references indexed in Scilit:
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeJournal of Clinical Investigation, 2017
- Adaptive Randomization of Neratinib in Early Breast CancerNew England Journal of Medicine, 2016
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerNew England Journal of Medicine, 2016
- Gene expression markers of Tumor Infiltrating LeukocytesbioRxiv, 2016
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast CancerNew England Journal of Medicine, 2016
- The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune ContextPLOS ONE, 2013
- Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersBreast Cancer Research, 2013
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibBreast Cancer Research and Treatment, 2012
- Adaptive clinical trials in oncologyNature Reviews Clinical Oncology, 2011
- T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersBreast Cancer Research, 2009